scholarly journals Infliximab: A Review of its use in the Treatment of Pediatric Crohn's Disease

2010 ◽  
Vol 2 ◽  
pp. CMT.S2840
Author(s):  
Arkady Broder ◽  
Joel R. Rosh
Keyword(s):  
Monoclonal Antibodies ◽  
Crohn’S Disease ◽  
Chronic Disease ◽  
Crohn's Disease ◽  
Tumor Necrosis ◽  
Immune Dysregulation ◽  
Necrosis Factor Alpha ◽  
The Past ◽  
Factor Alpha ◽  
Necrosis Factor

The past decade has brought great change to the treatment of pediatric Crohn's disease. The majority of affected patients now receive therapy directed at the underlying immune dysregulation that is associated with this chronic disease. The monoclonal antibodies directed against tumor necrosis factor alpha play an increasing role in such therapy. Infliximab is the prototype of this class of biologic based therapy. This review covers the basic pharmacokinetics of infliximab while reviewing the data on its efficacy in pediatric Crohn's disease patients. Current issues related to infliximab dosing and safety are also reviewed.

scholarly journals Esophageal post-inflammatory polyposis in extensive and severe Crohn’s disease treated with anti-tumor necrosis factor alpha

Endoscopy ◽  
2016 ◽  
Vol 48 (S 01) ◽  
pp. E261-E262 ◽  
Author(s):  
Paola Soriani ◽  
Gian Tontini ◽  
Helmut Neumann ◽  
Sauid Ishaq ◽  
Maria Annunziata ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Tumor Necrosis Factor ◽  
Crohn's Disease ◽  
Tumor Necrosis Factor Alpha ◽  
Tumor Necrosis ◽  
Necrosis Factor Alpha ◽  
Factor Alpha ◽  
Inflammatory Polyposis ◽  
Necrosis Factor

Short-term outcomes of laparoscopic surgery for Crohn’s disease patients treated with anti-tumor necrosis factor alpha agents

Surgery Today ◽  
2016 ◽  
Vol 47 (3) ◽  
pp. 320-327 ◽  
Author(s):  
Tsuyoshi Hata ◽  
Tsunekazu Mizushima ◽  
Hideki Osawa ◽  
Hidekazu Takahashi ◽  
Naotsugu Haraguchi ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Laparoscopic Surgery ◽  
Tumor Necrosis Factor ◽  
Crohn's Disease ◽  
Tumor Necrosis Factor Alpha ◽  
Tumor Necrosis ◽  
Short Term ◽  
Necrosis Factor Alpha ◽  
Factor Alpha ◽  
Necrosis Factor

scholarly journals Adalimumab-induced platelet antibodies resulting in severe thrombocytopenia

2021 ◽  
Author(s):  
Henk-Jan Boiten ◽  
Sufia Amini ◽  
Frank Wolfhagen ◽  
Peter Westerweel
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Laboratory Tests ◽  
Tumor Necrosis ◽  
Bone Marrow Suppression ◽  
Severe Thrombocytopenia ◽  
Necrosis Factor Alpha ◽  
Platelet Antibodies ◽  
Factor Alpha ◽  
Necrosis Factor

Anti-tumor necrosis factor alpha (TNFα) agents are effective in diseases including Crohn’s disease (CD) but may cause cytopenias. The mechanisms involved in anti-TNFα agents induced thrombocytopenia are scarce. We report a 73-year-old male with Crohn’s disease for which he currently used adalimumab, an anti-TNFα agent. He had received mesalazine and infliximab before the treatment of adalimumab. No comorbidities were present. Routine laboratory tests revealed a deep thrombocytopenia (thrombocytes 24x10*9/L) after which adalimumab was discontinued. Bleeding symptoms included cutaneous hematomas and mild epistaxis. Direct monoclonal antibody-specific immobilization of platelet antigens (MAIPA assay) revealed autoantibodies specific to glycoprotein IIb/IIIa (GPIIb/IIIa) and glycoprotein V (GPV) platelet receptors. There was no bone marrow suppression. Other causes of the thrombocytopenia were ruled out. The platelet count normalized after adalimumab discontinuation. No further interventions were required. Monitoring thrombocyte levels after initiating anti-TNFα agents is recommended, which could lead to prevention of this potential fatal phenomenon.

Sign in / Sign up

Export Citation Format

Share Document